Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome: Final appraisal document

DRAFT guidance does not recommend use as trial data are very uncertain; mogamulizumab was compared with vorinostat, a treatment that is not used or licensed in UK, and collecting further data is unlikely to address the clinical uncertainty because of limitations in trial design.

Source:

National Institute for Health and Care Excellence